Seeking Alpha
21 Sept 2026, 18:52 UTC · 1h ago
Verdict
Source says Upgrade. We score GRAL +0.80 across two claims.
Score confirms the headline.
Upgrade
Rating stated in the headline
+0.80strongly bullish
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
FDA briefing notes on the Galleri cancer test show high specificity of 99.6% and PPV up to 77%.
Newpublished Sep 21, 2026, references 'today' stock surge
So whatPositive AdCom outcomes typically trigger immediate valuation re-ratings for biotech firms awaiting FDA approval.
More positive than 99% of claims this week
GRAIL (GRAL) stock price increased by more than 30% in early trading on September 21, 2026.
Continue reading
5 related stories
More positive than 84% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Newpublished Sep 21, 2026, mentions 'today'
More positive than 76% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
Stock surged over 30% due to optimistic FDA briefing notes and a Buy rating upgrade.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
57m ago
+33.7%
Price agrees with the score
$107.97 vs $80.77 close before publication (Sep 18) · not market-adjusted
GRAL chart →
